Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory
Seminars in Cancer Biology, ISSN: 1044-579X, Vol: 86, Issue: Pt 2, Page: 386-395
2022
- 9Citations
- 12Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef4
- Captures12
- Readers12
- 12
Review Description
Treatment for small cell lung cancer (SCLC) has not changed significantly compared to the overwhelming development of targeted therapies for non-small cell lung cancer. However, recent epigenetic and expressional analyses have revealed that SCLC can be divided into four distinct subtypes, which may lead to precision treatments. The situation appears slightly similar to the "four-color problem," a classic mathematical problem stating that no more than four colors are required to color the regions so that no two adjacent areas have the same color. This review introduces the framework for subtyping SCLC into four molecular subtypes and the promising targeted treatment for each subtype.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1044579X2200116X; http://dx.doi.org/10.1016/j.semcancer.2022.05.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85130389945&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35569741; https://linkinghub.elsevier.com/retrieve/pii/S1044579X2200116X; https://dx.doi.org/10.1016/j.semcancer.2022.05.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know